PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Category:
Sort By:
Sep 21, 2020
A 2017 study from the American Optometric Association found that more than 16 million Americans are affected by dry eye disease (DED), also known as dry eye syndrome (DES), including nearly twice as many women as men. There is no single cause for eye dryness. It can be temporary or chronic and result from a...Read more
ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that after the conclusion of 4-years of extensive testing, evidence of fully functional retinal cells was conclusively achieved. Based on these results Dr. Kevin Gregory-Evans shortly submitting a paper for publication in a peer reviewed journal.   In vivo tests demonstrated that...Read more
Marietta, Ohio, August 27, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that Dr. James Shapiro has received approval from Health Canada and the University of Alberta Ethics Committee for the ammendments to the clinical trial protocol. This phase of the clinical trials, based on safety data received from...Read more
Aug 21, 2020
While there is currently no cure for diabetes, we believe our anti-aging glycopeptide, AAGP®, may be the essential link to the successful treatments of tomorrow. In preliminary testing, AAGP® has been shown to have protective properties that could help with the causes and consequences of this difficult disease. If you are interested in getting involved in...Read more
Marietta, Ohio, August 14, 2020                                                                                                         ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that due the results that AAGP® has achieved over the previous years, we are now moving into whole organ transplantation, open heart surgery and cardiac ischemia treatment testing. “In our in vitro model of rat...Read more
Jul 20, 2020
For anyone living with Type 1 diabetes, there is no doubt it is a challenging illness. Type 1 diabetes occurs at no fault of the patient, but unfortunately, there is no known cause or cure. ProtoKinetix researchers are actively exploring the potential for our anti-aging glycopeptide, AAGP®, to make better treatments possible. Continue reading to learn...Read more
Jul 14, 2020
When you are diagnosed with diabetes, you might initially feel overwhelmed and helpless. This chronic condition isn’t easy to live with all the time, since there are physical side effects of diabetes, as well as emotional and mental effects. Fortunately, there is active research being done to help uncover a cure, including studies conducted by...Read more
Jul 13, 2020
According to the Centers for Disease Control and Prevention (CDC), there were more than 30.3 million diagnosed cases of diabetes in the U.S. in 2015, and more than 100 million Americans are living with diabetes or prediabetes. While there is currently no cure, active research is being done, including studies by ProtoKinetix principal investigators to uncover...Read more
Marietta, Ohio, July 13, 2020                                                                                                              ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced an update to the Press Release of March 24, 2020. The amendments to the clinical trial protocol have been submitted by the University of Alberta to Health Canada for their review.  Upon approval from Health Canada and...Read more
Marietta, Ohio, July 7, 2020                                                                                                                ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX), a clinical-stage biomedical company, provides the following update regarding upcoming news in its Dry Eye Disease Program.   Dry Eye Disease (DED) – ProtoKinetix is expecting closure of agreements for the first steps in a roll-out of a new product...Read more

Subscribe for updates

Get alerts about company news and key findings directly in your inbox.

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.

Picture of a molecule
Picture of a molecule